# The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer

> **NCT06215976** · PHASE4 · RECRUITING · sponsor: **Cairo University** · enrollment: 78 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma

## Interventions

- **DRUG:** Metformin Hydrochloride 500 MG

## Key facts

- **NCT ID:** NCT06215976
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06215976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06215976, "The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06215976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*